Telotristat Etiprate for Carcinoid Syndrome Therapy
Status:
Completed
Trial end date:
2016-03-29
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the effect of telotristat etiprate versus placebo on
the incidence of treatment-emergent adverse events and on 5-hydroxyindoleacetic acid (5-HIAA)
levels.